Novo Nordisk Q2 2026 adjusted operating profit rises 11% to DKK 33.39 billion; adjusted sales increase 7% to DKK 78.49 billion

• Novo Nordisk posted Q2 2026 adjusted sales of DKK 78.49 billion, up 7% from a year earlier.
• Adjusted operating profit rose 11% to DKK 33.39 billion.
• Raised 2026 outlook for adjusted sales growth to 0% to -6% from -4% to -12%.
• Lifted adjusted operating profit growth view to 0% to -6% from -4% to -12%, citing higher expectations for GLP-1 product sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608041233OMX_____CNEWS_EN_GNW1001256041_en) on August 04, 2026, and is solely responsible for the information contained therein.